Literature DB >> 3421344

DSM-III-R criteria for posttraumatic stress disorder.

E A Brett1, R L Spitzer, J B Williams.   

Abstract

The authors describe the changes in DSM-III criteria for posttraumatic stress disorder (PTSD) that have been included in DSM-III-R. DSM-III-R includes specification of generic characteristics of traumatic stressors, clearer organization of symptoms around three dimensions of stress response (reexperiencing, avoidance and numbing, and physiological arousal), inclusion of symptoms specific to children, and specification of onset and duration of the disorder. The importance of these changes in the evolution of the diagnosis of PTSD is discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3421344     DOI: 10.1176/ajp.145.10.1232

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  5 in total

1.  PTSD prevalence, associated exposures, and functional health outcomes in a large, population-based military cohort.

Authors:  Tyler C Smith; Deborah L Wingard; Margaret A K Ryan; Donna Kritz-Silverstein; Donald J Slymen; James F Sallis
Journal:  Public Health Rep       Date:  2009 Jan-Feb       Impact factor: 2.792

2.  Post-traumatic stress disorder and coping after a natural disaster.

Authors:  M T Spurrell; A C McFarlane
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1993-08       Impact factor: 4.328

3.  Posttraumatic stress disorder in persons with developmental disabilities.

Authors:  R Ryan
Journal:  Community Ment Health J       Date:  1994-02

4.  Reconciling disparate prevalence rates of PTSD in large samples of US male Vietnam veterans and their controls.

Authors:  William W Thompson; Irving I Gottesman; Christine Zalewski
Journal:  BMC Psychiatry       Date:  2006-05-02       Impact factor: 3.630

5.  Latent profile analysis and principal axis factoring of the DSM-5 dissociative subtype.

Authors:  Paul A Frewen; Matthew F D Brown; Carolin Steuwe; Ruth A Lanius
Journal:  Eur J Psychotraumatol       Date:  2015-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.